Page last updated: 2024-12-05

4-hydroxyphenobarbital

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID9785
CHEMBL ID1908024
CHEBI ID180569
MeSH IDM0068132

Synonyms (35)

Synonym
CHEBI:180569
5-ethyl-5-(4-hydroxyphenyl)-1,3-diazinane-2,4,6-trione
hydroxyphenobarbitone,p-
2,4,6(1h,3h,5h)-pyrimidinetrione, 5-ethyl-5-(4-hydroxyphenyl)-
nsc-159266
379-34-0
nsc159266
4-hydroxyphenobarbital
5-ethyl-5-(p-hydroxyphenyl)barbituric acid
p-hydroxyphenobarbitone
4-hydroxy phenobarbital
5-ethyl-5-(p-hydroxy-phenyl)barbituric acid
CHEMBL1908024
p-hydroxy-pb
nsc 159266
5-ethyl-5-(4-hydroxyphenyl)-2,4,6(1h,3h,5h)-pyrimidinetrione
p-hydroxy-phenobarbitone
unii-rf9r6t1nun
rf9r6t1nun ,
para-hydroxyphenobarbital
p-hydroxyphenobarbital
einecs 206-831-7
5-ethyl-5-(4'-hydroxyphenyl)barbituric acid monohydrate
2,4,6(1h,3h,5h)-pyrimidinetrione,5-ethyl-5-(4-hydroxyphenyl)-
5-ethyl-5-(p-hydroxy-phenyl)-barbituric acid
IEPXMKJNWPXDBP-UHFFFAOYSA-N
phenobarbital-p-hydroxy
5-ethyl-5-(4-hydroxyphenyl)-2,4,6(1h,3h,5h)-pyrimidinetrione #
DTXSID20191328
AKOS030255840
5-ethyl-5-(p-hydroxy- phenyl)barbituric acid
5-(p-hydroxyphenyl)-5-ethylbarbituric acid
barbituric acid, 5-ethyl-5-(p-hydroxyphenyl)-
5-ethyl-5-(4-hydroxyphenyl)barbituric acid
hydroxyphenobarbital

Research Excerpts

Pharmacokinetics

ExcerptReferenceRelevance
" The pharmacokinetics of phenobarbital were studied in a separate set of rats (elimination half-life 11 +/- 2 hr)."( Pharmacokinetic modeling of the anticonvulsant action of phenobarbital in rats.
Danhof, M; Dingemanse, J; van Bree, JB, 1989
)
0.28
" Pharmacokinetic parameters of phenobarbital and parahydroxyphenobarbital were determined from plasma and urine samples obtained after 28 days of daily administration of 100 mg phenobarbital and after a further 9 days of phenobarbital plus 2400 mg/day felbamate or placebo."( Effects of felbamate on the pharmacokinetics of phenobarbital.
Banfield, CR; Colucci, RD; Glue, P; Guillaume, M; Lin, CC; Meehan, JW; Mojavarian, P; Nezamis, J; Radwanski, E; Reidenberg, P, 1995
)
0.29

Dosage Studied

ExcerptRelevanceReference
" Following ip dosing of the mouse with the phenobarbital N-glucosides, free phenobarbital could be detected in the urine."( Identification of phenobarbital N-glucosides as urinary metabolites of phenobarbital in mice.
Agriesti, BE; England, TM; Ferkany, JW; Soine, PJ; Soine, WH, 1991
)
0.28
"A method suitable for pulse dosing studies is described for the quantitation by gas chromatography mass spectrometry of phenobarbital (5-ethyl-5-phenylbarbituric acid), p-hydroxyphenobarbital (5-ethyl-5(4-hydroxyphenyl)barbituric acid) and, simultaneously, their (13C15N2)-labeled analogs in serum and urine."( Simultaneous determination of phenobarbital and p-hydroxyphenobarbital and their stable isotope labeled analogs by gas chromatography mass spectrometry.
Biemann, K; Biller, JE; Browne, TR; Van Langenhove, A, 1982
)
0.26
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
barbituratesMembers of the class of pyrimidones consisting of pyrimidine-2,4,6(1H,3H,5H)-trione (barbituric acid) and its derivatives. Largest group of the synthetic sedative/hypnotics, sharing a characteristic six-membered ring structure.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Bioassays (1)

Assay IDTitleYearJournalArticle
AID624619Specific activity of expressed human recombinant UGT2B72000Annual review of pharmacology and toxicology, , Volume: 40Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (35)

TimeframeStudies, This Drug (%)All Drugs %
pre-199020 (57.14)18.7374
1990's11 (31.43)18.2507
2000's3 (8.57)29.6817
2010's1 (2.86)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 10.49

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index10.49 (24.57)
Research Supply Index3.61 (2.92)
Research Growth Index4.10 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (10.49)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (2.86%)5.53%
Reviews1 (2.86%)6.00%
Case Studies1 (2.86%)4.05%
Observational0 (0.00%)0.25%
Other32 (91.43%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]